Apretude

Recent studies have defined an appropriate CAB LA dosing interval and offered insight into its safety profile. Phase 3 studies will provide much-anticipated efficacy data. If efficacious, CAB LA may provide a desirable PrEP option for those who face challenges to daily pill adherence. A more complete understanding of how to best integrate LA PrEP […]

An update on HPTN 083, the study that established that PrEP given as an injection every two months had superior efficacy to a daily pill in gay and bisexual men and transgender women, was presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2022).

This study assess the terminal phase pharmacokinetics and safety of long-acting injectable cabotegravir in participants included in the HPTN 077 trial.

Long-acting injectable PrEP acceptability was high, especially at non-U.S. sites. Preferences for a LAI PrEP product compared to other methods was higher among males, many who were MSM, in the U.S., and higher among females in non-U.S. compared to U.S. sites, where both the need for new HIV prevention methods is greatest and contraceptive injectable

The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo.

This study aimed to assess the safety, tolerability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not at high risk of HIV-1 infection.

HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.

This study assessed the effect of nanoparticles (NMCAB) on the biodistribution and viral clearance profiles of current CAB LAP formulations.

Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience.

HPTN/IMPAACT Network Meeting 2016 Presentation